PURAPHARM (01498) announced that the group expects to incur a net loss of no more than approximately 36... for the fiscal year 2024.
Zhitong Finance APP reported that PURAPHARM (01498) announced that the group is expected to achieve a net loss of no more than approximately 36 million Hong Kong dollars for the fiscal year 2024, while a consolidated net loss of approximately 0.1061 billion Hong Kong dollars was recorded for the year ended December 31, 2023. The significant reduction in the consolidated net loss for fiscal year 2024 is mainly attributable to the decrease in impairment losses related to properties, plants, and equipment, as well as goodwill associated with the group's planting segment; the decrease in fair value losses of biological assets related to the group's planting segment, as they were fully impaired by the end of the fiscal year 2023; and a significant reduction in administrative and selling and distribution expenses as a result of the group’s cost control activities.
Comment(0)
Reason For Report